Nongenomic Mechanisms of Endothelial Nitric Oxide Synthase Activation by the Selective Estrogen Receptor Modulator Raloxifene
Open Access
- 19 March 2002
- journal article
- other
- Published by Wolters Kluwer Health in Circulation
- Vol. 105 (11) , 1368-1373
Abstract
Background — Nontranscriptional signaling through estrogen receptors (ERs) is important in the cardiovascular system. In particular, estrogen stimulates endothelial NO synthase (eNOS) via the phosphatidylinositol 3-kinase (PI3K) pathway. The selective estrogen receptor modulator (SERM) raloxifene is effective for the treatment of postmenopausal osteoporosis, but its ability to activate eNOS via PI3K is unknown. Methods and Results — Human umbilical vein endothelial cells were cultured in estrogen-deprived, phenol red-free medium. Raloxifene stimulated eNOS in a concentration- and time-dependent manner. Activation of eNOS by raloxifene was blocked by the PI3K inhibitor wortmannin and by the ER antagonist ICI 182,780 but not by transcriptional or translational inhibitors. Coimmunoprecipitation studies demonstrated that, in a ligand-dependent manner, raloxifene increased ERα-associated p85α, p110α, and PI3K activity. This correlated temporally with increases in the serine and threonine phosphorylation and activation of protein kinase Akt. Conclusions — Our findings indicate that nongenomic ER signaling triggered by a SERM leads to a rapid activation of NO synthesis in human endothelial cells. The ability of raloxifene to facilitate ERα-PI3K interaction may provide additional insight into the structure-function relationship of specific SERMs, which promote the nontranscriptional effects of ER.Keywords
This publication has 24 references indexed in Scilit:
- Estrogen Induces the Akt-dependent Activation of Endothelial Nitric-oxide Synthase in Vascular Endothelial CellsJournal of Biological Chemistry, 2001
- Effects of Estrogen Replacement on the Progression of Coronary-Artery AtherosclerosisNew England Journal of Medicine, 2000
- Cardiovascular disease and hormone replacement therapyClimacteric, 2000
- Structure of the ligand‐binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonistThe EMBO Journal, 1999
- Estrogen receptor α mediates the nongenomic activation of endothelial nitric oxide synthase by estrogenJournal of Clinical Investigation, 1999
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJAMA, 1998
- Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal WomenNew England Journal of Medicine, 1997
- Cardiovascular Medicine at the Turn of the Millennium: Triumphs, Concerns, and OpportunitiesNew England Journal of Medicine, 1997
- ERβ: Identification and characterization of a novel human estrogen receptorFEBS Letters, 1996
- Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines.Journal of Clinical Investigation, 1995